NasdaqGS - Delayed Quote • USD
NextCure, Inc. (NXTC)
At close: April 23 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.46 | -0.41 | -1.67 | -1.68 |
| Low Estimate | -0.51 | -0.43 | -1.78 | -1.97 |
| High Estimate | -0.43 | -0.36 | -1.47 | -1.4 |
| Year Ago EPS | -0.58 | -0.64 | -2.25 | -1.67 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.64 | -0.59 | -0.66 | -0.54 |
| EPS Actual | -0.58 | -0.64 | -0.51 | -0.52 |
| Difference | 0.06 | -0.05 | 0.15 | 0.02 |
| Surprise % | 9.40% | -8.50% | 22.70% | 3.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.46 | -0.41 | -1.67 | -1.68 |
| 7 Days Ago | -0.46 | -0.41 | -1.67 | -1.68 |
| 30 Days Ago | -0.47 | -0.45 | -2.02 | -1.72 |
| 60 Days Ago | -0.59 | -0.61 | -2.54 | -1.76 |
| 90 Days Ago | -0.59 | -0.61 | -2.54 | -1.76 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NXTC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 20.70% | -- | -- | 0.40% |
| Next Qtr. | 35.90% | -- | -- | 9.90% |
| Current Year | 25.80% | -- | -- | 4.30% |
| Next Year | -0.60% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -31.70% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/22/2024 |
| Maintains | Needham: Buy to Buy | 3/20/2024 |
| Maintains | Needham: Buy to Buy | 12/14/2023 |
| Initiated | HC Wainwright & Co.: Buy | 8/8/2023 |
| Reiterates | Needham: Buy to Buy | 8/4/2023 |
| Reiterates | Needham: Buy | 5/5/2023 |
Related Tickers
CTMX CytomX Therapeutics, Inc.
1.6800
+0.60%
ASMB Assembly Biosciences, Inc.
13.27
+0.38%
EIGRQ Eiger BioPharmaceuticals, Inc.
3.9500
-1.25%
GLPG.AS Galapagos NV
27.56
+0.80%
ACHL Achilles Therapeutics plc
0.7811
-2.24%
TIL Instil Bio, Inc.
10.75
+0.37%
SPRO Spero Therapeutics, Inc.
1.4350
+2.14%
PRTC.L PureTech Health plc
213.00
+3.65%
CLRB Cellectar Biosciences, Inc.
3.1100
-2.51%
RPHM Reneo Pharmaceuticals, Inc.
1.6750
-0.89%